129 related articles for article (PubMed ID: 18047852)
1. Novel peroxisome proliferator activated receptor-alpha agonists.
Fruchart JC
Am J Cardiol; 2007 Dec; 100(11 A):n41-6. PubMed ID: 18047852
[TBL] [Abstract][Full Text] [Related]
2. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
3. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
4. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
[TBL] [Abstract][Full Text] [Related]
5. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
7. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias.
Yong EL; Li J; Liu MH
Curr Opin Lipidol; 2008 Apr; 19(2):106-12. PubMed ID: 18388689
[TBL] [Abstract][Full Text] [Related]
8. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
9. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
Kawada T; Goto T; Hirai S; Kang MS; Uemura T; Yu R; Takahashi N
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():126-30. PubMed ID: 18296319
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis.
Staumont-Sallé D; Abboud G; Brénuchon C; Kanda A; Roumier T; Lavogiez C; Fleury S; Rémy P; Papin JP; Bertrand-Michel J; Tercé F; Staels B; Delaporte E; Capron M; Dombrowicz D
J Allergy Clin Immunol; 2008 Apr; 121(4):962-8.e6. PubMed ID: 18249437
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Giaginis C; Tsantili-Kakoulidou A; Theocharis S
Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
[TBL] [Abstract][Full Text] [Related]
12. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
13. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
[TBL] [Abstract][Full Text] [Related]
14. PPAR and Pain.
Maeda T; Kishioka S
Int Rev Neurobiol; 2009; 85():165-77. PubMed ID: 19607969
[TBL] [Abstract][Full Text] [Related]
15. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Curr Opin Pharmacol; 2005 Apr; 5(2):177-83. PubMed ID: 15780828
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
Smeets PJ; Planavila A; van der Vusse GJ; van Bilsen M
Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
[TBL] [Abstract][Full Text] [Related]
17. PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease.
Asnani S; Theuma P; Fonseca VA
Metab Syndr Relat Disord; 2003 Mar; 1(1):23-32. PubMed ID: 18370623
[TBL] [Abstract][Full Text] [Related]
18. [Fibrates and markers of inflammation].
Broncel M
Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
[TBL] [Abstract][Full Text] [Related]
19. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
Collino M; Patel NS; Thiemermann C
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):179-97. PubMed ID: 19124421
[TBL] [Abstract][Full Text] [Related]
20. PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells.
Rival Y; Puech L; Taillandier T; Benéteau N; Rouquette A; Lestienne F; Dupont-Passelaigue E; Le Roy I; Patoiseau JF; Junquéro D
Eur J Pharmacol; 2009 Mar; 606(1-3):121-9. PubMed ID: 19374865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
